NewsCoronavirus

Actions

Johnson & Johnson's single-shot vaccine proves effective in trial, but less so than Moderna, Pfizer

Johnson & Johnson releases results from COVID vaccine trial
Johnson & Johnson COVID-19 Vaccine
Posted
and last updated

Johnson & Johnson says its single-shot COVID-19 vaccine is effective in preventing severe cases of COVID-19, but not as well as other two-shot variants of the vaccine that are already on the market.

The company released results from its Phase 3 trial on Friday, saying that it was 66% effective in preventing moderate to severe cases of the virus, and 85% effective in preventing the most severe cases of COVID-19.

By contrast, two-shot vaccines made by Pfizer and Moderna were both more than 90% effective in preventing COVID-19. However, because the Johnson & Johnson shot only requires a single dose, a large supply of the vaccine could potentially solve some logistical problems in widespread distribution.

Johnson & Johnson also said that the vaccine candidate performed better in the U.S. than it did in South Africa, where a mutated form of the virus is spreading throughout the country. According to the Associated Press, the vaccine was 72% effective in preventing moderate to severe cases of COVID-19 in the U.S., while only 57% effective in South Africa.

The company says it will file for Emergency Use Authorization within a week. Johnson & Johnson has already committed to providing 100 million doses of the vaccine by June and could provide doses as soon as it is cleared by the CDC and FDA.

,

Weather

Daily Forecast

View Hourly Forecast

Day

Conditions

HI / LO

Precip

Thursday

07/03/2025

Clear

-° / 69°

0%

Friday

07/04/2025

Clear

95° / 65°

0%

Saturday

07/05/2025

Clear

95° / 65°

0%

Sunday

07/06/2025

Clear

99° / 69°

0%

Monday

07/07/2025

Clear

101° / 69°

0%

Tuesday

07/08/2025

Clear

101° / 70°

0%

Wednesday

07/09/2025

Clear

101° / 73°

0%

Thursday

07/10/2025

Clear

102° / 75°

0%